Jiahui Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jiahui Yang has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Kaifeng Hu
Innovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China
11 shared publications Yanping Li
Chengdu Univ Tradit Chinese Med, Sch Basic Med, 1166 Liutai Ave, Chengdu 611137, Sichuan, Peoples R China
7 shared publicationsXiaoqian Xiao
School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China
5 shared publicationsYuxi Zhang
School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China
5 shared publicationsCaihong Bai
School of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China
4 shared publicationsJingyi Tang
School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 611137, China
4 shared publications
Latest Publications
- 21 July 2025
- Published by Elsevier in Phytomedicine
- Vol. 146, 157085
Artesunate modulates the tumor microenvironment via STAT1/IRF1-mediated TAM repolarization and T cell activation in non-small cell lung cancer
- 21 July 2025
- Published by Elsevier in Phytomedicine
- Vol. 146, 157085
Artesunate modulates the tumor microenvironment via STAT1/IRF1-mediated TAM repolarization and T cell activation in non-small cell lung cancer
- 28 May 2024
- Published by Elsevier in Carbohydrate Research
- Vol. 541, 109168
Monosaccharide composition analysis by 2D quantitative gsHSQCi
- 28 May 2024
- Published by Elsevier in Carbohydrate Research
- Vol. 541, 109168
Monosaccharide composition analysis by 2D quantitative gsHSQCi
- 3 May 2024
- Published by Wiley in Chemistry & Biodiversity
- Vol. 21 (6) , e202400258
Identifying Anti‐NSCLC Bioactive Compounds in Scutellaria via 2D NMR‐Based Metabolomic Analysis of Pharmacologically Classified Crude Extracts
We presented a strategy utilizing 2D NMR‐based metabolomic analysis of crude extracts, categorized by different pharmacological activities, to rapidly identify the primary bioactive components of TCM. It was applied to identify the potential bioactive components from Scutellaria crude extracts that exhibit anti‐non‐small cell lung cancer (anti‐NSCLC) activity. Four Scutellaria species were chosen as the study subjects because of their close phylogenetic relationship, but their crude extracts exhibit significantly different anti‐NSCLC activity. Cell proliferation assay was used to assess the anti‐NSCLC activity of four species of Scutellaria. 1H−13C HSQC spectra were acquired for the chemical profiling of these crude extracts. Based on the pharmacological classification (PCA, OPLS‐DA and univariate hypothesis test) were performed to identify the bioactive constituents in Scutellaria associated with the anti‐NSCLC activity. As a result, three compounds, baicalein, wogonin and scutellarin were identified as bioactive compounds. The anti‐NSCLC activity of the three potential active compounds were further confirmed via cell proliferation assay. The mechanism of the anti‐NSCLC activity by these active constituents was further explored via flow cytometry and western blot analyses. This study demonstrated 2D NMR‐based metabolomic analysis of pharmacologically classified crude extracts to be an efficient approach to the identification of active components of herbal medicine.
- 3 May 2024
- Published by Wiley in Chemistry & Biodiversity
- Vol. 21 (6) , e202400258
Identifying Anti‐NSCLC Bioactive Compounds in Scutellaria via 2D NMR‐Based Metabolomic Analysis of Pharmacologically Classified Crude Extracts
We presented a strategy utilizing 2D NMR‐based metabolomic analysis of crude extracts, categorized by different pharmacological activities, to rapidly identify the primary bioactive components of TCM. It was applied to identify the potential bioactive components from Scutellaria crude extracts that exhibit anti‐non‐small cell lung cancer (anti‐NSCLC) activity. Four Scutellaria species were chosen as the study subjects because of their close phylogenetic relationship, but their crude extracts exhibit significantly different anti‐NSCLC activity. Cell proliferation assay was used to assess the anti‐NSCLC activity of four species of Scutellaria. 1H−13C HSQC spectra were acquired for the chemical profiling of these crude extracts. Based on the pharmacological classification (PCA, OPLS‐DA and univariate hypothesis test) were performed to identify the bioactive constituents in Scutellaria associated with the anti‐NSCLC activity. As a result, three compounds, baicalein, wogonin and scutellarin were identified as bioactive compounds. The anti‐NSCLC activity of the three potential active compounds were further confirmed via cell proliferation assay. The mechanism of the anti‐NSCLC activity by these active constituents was further explored via flow cytometry and western blot analyses. This study demonstrated 2D NMR‐based metabolomic analysis of pharmacologically classified crude extracts to be an efficient approach to the identification of active components of herbal medicine.
- 27 April 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 133, 112157
Dihydroartemisinin inhibits tumor progress via blocking ROR1-induced STAT3-activation in non-small cell lung cancer
- 27 April 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 133, 112157
Dihydroartemisinin inhibits tumor progress via blocking ROR1-induced STAT3-activation in non-small cell lung cancer
- 25 July 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 123, 110686
Antitumor activity of a ROR1 × CD3 bispecific antibody in non-small cell lung cancer
- 25 July 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 123, 110686
Antitumor activity of a ROR1 × CD3 bispecific antibody in non-small cell lung cancer
- 8 February 2022
- Published by Elsevier in Biochemical Pharmacology
- Vol. 198, 114941
Dihydroartemisinin and artesunate inhibit aerobic glycolysis via suppressing c-Myc signaling in non-small cell lung cancer
- 8 February 2022
- Published by Elsevier in Biochemical Pharmacology
- Vol. 198, 114941
Dihydroartemisinin and artesunate inhibit aerobic glycolysis via suppressing c-Myc signaling in non-small cell lung cancer